| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20058177 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20041182 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20058236 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20058541 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20058450 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20058625 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS20058973 | HPV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS44005801 | HTLV-1 | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS44030180 | HTLV-1 | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS44022244 | HTLV-1 | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NR3C2 |
|---|---|
| DrugBank ID | DB00421 |
| Drug Name | Spironolactone |
| Target ID | BE0000668 |
| UniProt ID | P08235 |
| Regulation Type | antagonist |
| PubMed IDs | 11791081; 14664717; 14978157; 15128471; 15554912; 11752352; 15947888; 15808807 |
| Citations | Sitruk-Ware R: Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause. 2002 Jan-Feb;9(1):6-15.@@Rogerson FM, Yao YZ, Smith BJ, Dimopoulos N, Fuller PJ: Determinants of spironolactone binding specificity in the mineralocorticoid receptor. J Mol Endocrinol. 2003 Dec;31(3):573-82.@@Gertner RA, Klein JD, Bailey JL, Kim DU, Luo XH, Bagnasco SM, Sands JM: Aldosterone decreases UT-A1 urea transporter expression via the mineralocorticoid receptor. J Am Soc Nephrol. 2004 Mar;15(3):558-65.@@Frishman WH, Stier CT Jr: Aldosterone and aldosterone antagonism in systemic hypertension. Curr Hypertens Rep. 2004 Jun;6(3):195-200.@@Rogerson FM, Yao Y, Smith BJ, Fuller PJ: Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Clin Exp Pharmacol Physiol. 2004 Oct;31(10):704-9.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Sica DA: Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005 Jan;10(1):23-9. doi: 10.1007/s10741-005-2345-1.@@Rossi G, Boscaro M, Ronconi V, Funder JW: Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab. 2005 Apr;16(3):104-7. |
| Groups | Approved |
| Direct Classification | Spironolactones and derivatives |
| SMILES | [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O |
| Pathways | Spironolactone Action Pathway |
| PharmGKB | PA451483 |
| ChEMBL | CHEMBL1393 |
